Viewing Study NCT05507632

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:49 PM
Ignite Modification Date: 2026-01-31 @ 4:53 PM
Study NCT ID: NCT05507632
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-08-19
First Post: 2022-08-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Sponsor: Nanfang Hospital, Southern Medical University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Unresectable Hepatocellular Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None hepatocellular carcinoma View
None HCC View
None Donafenib View
None Sintilimab View
None transarterial chemoembolisation View